Furthermore, Trz is not only used in combination with other chemotherapeutic agents, but is also used as a monotherapy, including in elderly patients with early HER2+ breast cancer (Sawaki et al. 2020; Konishi et al. 2022). This evidence concerns the gene ERBB2 and breast carcinoma.